Cargando…

Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life

Our aim is to determine—in 30 healthy full-term infants and their mothers—circulating levels of neurotrophin-3 (NT-3) (important for antenatal and postnatal brain development and implicated in the immune response) and FLT3 tyrosine kinase receptor (FLT3) (controlling hematopoiesis and found in the n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malamitsi-Puchner, Ariadne, Economou, Emmanouel, Boutsikou, Theodora, E. Nikolaou, Konstantinos, Vrachnis, Nikolaos
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2005
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513060/ https://www.ncbi.nlm.nih.gov/pubmed/15770067 http://dx.doi.org/10.1155/MI.2005.53

Ejemplares similares

Vascular Endothelial Growth Factor and Placenta Growth Factor in Intrauterine Growth-Restricted Fetuses and Neonates
por: Malamitsi-Puchner, Ariadne, et al.
Publicado: (2005)

Perinatal Plasma Monocyte Chemotactic Protein-1 Concentrations in Intrauterine Growth Restriction
por: Briana, Despina D., et al.
Publicado: (2007)

Cord Blood Ischemia-Modified Albumin Levels in Normal and Intrauterine Growth Restricted Pregnancies
por: Iacovidou, Nicoletta, et al.
Publicado: (2008)

Perinatal Changes of Cardiac Troponin-I in Normal and Intrauterine Growth-Restricted Pregnancies
por: Iacovidou, Nicoletta, et al.
Publicado: (2007)

Investigation of Midtrimester Amniotic Fluid Factors as Potential Predictors of Term and Preterm Deliveries
por: Malamitsi-Puchner, Ariadne, et al.
Publicado: (2006)

Cytokine soluble receptors in perinatal and early neonatal life.
por: Protonotariou, Efthimia, et al.
Publicado: (2003)

Circulating Levels of Inflammatory Markers in Intrauterine Growth Restriction
por: Boutsikou, Theodora, et al.
Publicado: (2010)

Insulin-Like Growth Factor (IGF)-I and Insulin in Normal and Growth-Restricted Mother/Infant Pairs
por: Malamitsi-Puchner, Ariadne, et al.
Publicado: (2007)

An Update on Lung Function of Extremely and Very Preterm Infants in Later Life: The Role of Early Nutritional Interventions
por: Briana, Despina D., et al.
Publicado: (2023)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Factors affecting human colostrum fatty acid profile: A case study
por: Sinanoglou, Vassilia J., et al.
Publicado: (2017)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

Low-Grade Systemic Inflammation Profile, Unrelated to Homocysteinemia, in Obese Children
por: V. Economou, Emanuel, et al.
Publicado: (2005)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Neurotrophin receptor tyrosine kinases regulated with near-infrared light
por: Leopold, Anna V., et al.
Publicado: (2019)

Activation of neurotrophin signalling with light-inducible receptor tyrosine kinases
por: Zhang, Wei, et al.
Publicado: (2022)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

Detection and Quantification of Neurotrophin-3 (NT-3) and Nerve Growth Factor (NGF) Levels in Early Second Trimester Amniotic Fluid: Investigation into a Possible Correlation with Abnormal Fetal Growth Velocity Patterns
por: Machairiotis, Nikolaos, et al.
Publicado: (2023)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
por: Smith, Amanda M., et al.
Publicado: (2016)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
por: Nguyen, Bao, et al.
Publicado: (2017)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Serum and Urinary N-Terminal Pro-brain Natriuretic Peptides as Biomarkers for Bronchopulmonary Dysplasia of Preterm Neonates
por: Iliodromiti, Zoi, et al.
Publicado: (2020)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
por: Grafone, Tiziana, et al.
Publicado: (2012)

Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice
por: Rivat, Cyril, et al.
Publicado: (2018)

FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
por: Ramos, Maria I, et al.
Publicado: (2013)

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
por: Kawase, Tatsuya, et al.
Publicado: (2019)

A role for the tyrosine kinase ACK1 in neurotrophin signaling and neuronal extension and branching
por: La Torre, A, et al.
Publicado: (2013)

SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
por: Guo, Yao, et al.
Publicado: (2012)

Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors
por: Manachai, Nawin, et al.
Publicado: (2022)

Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD
por: Schwarz, Marie, et al.
Publicado: (2022)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

Age-related differentiations of Th1/Th2 cytokines in newborn infants.
por: Protonotariou, Efthimia, et al.
Publicado: (2004)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
por: Ke, Yi-Yu, et al.
Publicado: (2015)

ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition
por: Ju, H-Q, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qqlogsn2qjpnrkbdhudk2t4qvk